Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria~* Males or females providing written, informed consent~* Histologically- or cytologically-confirmed advanced solid malignancy that is refractory to standard-of-care treatment, or for which there is no standard therapy. If this is glioma:Grade III / Grade IV malignant glioma recurring or progressing after first or second line standard-of-care treatment and true progressive disease, confirmed according to the RANO criteria 4.~* Life-expectancy of at least 12 weeks~* Eastern cooperative oncology group (ECOG) performance status of 0-2~* Safety laboratory tests and ECGs within specified limits.~* Using adequate contraception, where applicable~* Presence of lesions suitable for biopsy (mandatory for non-glioma patients enrolled in the expanded safety cohort and highly desirable for non-glioma patients enrolled in the dose escalation phase)~Exclusion Criteria~* Anti cancer therapy within 4 weeks (6 weeks for mitomycin and nitrosureas and 2 weeks for palliative radiotherapy)~* NCI Common terminology criteria for adverse events (CTCAE) \>Grade 1 toxicities from prior chemotherapy or radiotherapy that could impact on safety outcome assessment~* Recent \>Grade 1 intracranial or intratumoural haemorrhage either by CT or MRI scan. Patients with resolving haemorrhage changes, punctuate haemorrhage or haemosiderin may enter the study~* Significant or uncontrolled cardiovascular disease, unstable angina or myocardial infarction within the preceding 6 months~* Known impairment of GI function that could alter the absorption of study drug~* History of uncontrolled hyperlipidemia and/or the need for concurrent lipid lowering therapy~* Concurrent severe and/or uncontrolled other medical disease that could compromise participation in the study~* Taking warfarin, phenytoin or sulphonylureas (glibenclamide, glimepiride, glipizide, glyburide or nateglanide)~* Pregnant or breast feeding Other protocol specific criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Cohort 1 (Type: EXPERIMENTAL): Intervention: LAM561. 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
- Dose Cohort 2 (Type: EXPERIMENTAL): Intervention: LAM561. 500 mg twice daily
- Dose Cohort 3 (Type: EXPERIMENTAL): Intervention: LAM561.~1g twice daily
- LAM561 Dose Cohort 4 (Type: EXPERIMENTAL): Intervention: LAM561. 2g twice daily
- LAM561 Dose Cohort 5 (Type: EXPERIMENTAL): Intervention: LAM561. 4g twice daily
- LAM561Dose Cohort 6 (Type: EXPERIMENTAL): Intervention: LAM561. 4g three times daily
- LAM561 Dose Cohort 7 (Type: EXPERIMENTAL): Intervention: LAM561. 8g twice daily
- LAM561 Dose Expansion cohort. Glioma (Type: EXPERIMENTAL): Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
- LAM561 Dose Expansion cohort. Non-glioma (Type: EXPERIMENTAL): Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).